201 related articles for article (PubMed ID: 24761755)
1. Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.
Kumar V; Ridzwan IE; Grivas K; Lewis JW; Clark MJ; Meurice C; Jimenez-Gomez C; Pogozheva I; Mosberg H; Traynor JR; Husbands SM
J Med Chem; 2014 May; 57(10):4049-57. PubMed ID: 24761755
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
3. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
4. C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.
Cueva JP; Roche C; Ostovar M; Kumar V; Clark MJ; Hillhouse TM; Lewis JW; Traynor JR; Husbands SM
J Med Chem; 2015 May; 58(10):4242-9. PubMed ID: 25898137
[TBL] [Abstract][Full Text] [Related]
5. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
6. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
7. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
[TBL] [Abstract][Full Text] [Related]
8. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
Wtorek K; Janecka A
Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.
Kallupi M; Shen Q; de Guglielmo G; Yasuda D; Journigan VB; Zaveri NT; Ciccocioppo R
Addict Biol; 2018 Mar; 23(2):585-595. PubMed ID: 28635181
[TBL] [Abstract][Full Text] [Related]
11. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile.
Kuo A; Magiera J; Rethwan N; Andersson Å; Leen Lam A; Wyse B; Meutermans W; Lewis R; Smith M
Eur J Pharmacol; 2020 Apr; 872():172947. PubMed ID: 31991138
[TBL] [Abstract][Full Text] [Related]
12. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
Cami-Kobeci G; Polgar WE; Khroyan TV; Toll L; Husbands SM
J Med Chem; 2011 Oct; 54(19):6531-7. PubMed ID: 21866885
[TBL] [Abstract][Full Text] [Related]
13. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.
Khroyan TV; Wu J; Polgar WE; Cami-Kobeci G; Fotaki N; Husbands SM; Toll L
Br J Pharmacol; 2015 Jan; 172(2):668-80. PubMed ID: 24903063
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors.
Wang PC; Ho IK; Lee CW
J Cell Mol Med; 2015 Nov; 19(11):2587-96. PubMed ID: 26153065
[TBL] [Abstract][Full Text] [Related]
15. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
[TBL] [Abstract][Full Text] [Related]
16. Opioid Receptors in Immune and Glial Cells-Implications for Pain Control.
Machelska H; Celik MÖ
Front Immunol; 2020; 11():300. PubMed ID: 32194554
[TBL] [Abstract][Full Text] [Related]
17. Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.
Taylor AM; Roberts KW; Pradhan AA; Akbari HA; Walwyn W; Lutfy K; Carroll FI; Cahill CM; Evans CJ
Br J Pharmacol; 2015 Jan; 172(2):691-703. PubMed ID: 24923251
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).
Dietis N; McDonald J; Molinari S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Anaesth; 2012 Feb; 108(2):262-70. PubMed ID: 22194444
[TBL] [Abstract][Full Text] [Related]
19. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
[TBL] [Abstract][Full Text] [Related]
20. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
